- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02573818
Sedasys Post Approval Study Users Response to System Alarms
March 22, 2017 updated by: Ethicon Endo-Surgery
Open-Label Post Approval Study of the SEDASYS System User Response to System Alarms
The purpose of this study is to evaluate the users' responses to the SEDASYS® System alarms during esophagogastroduodenoscopy (EGD) or colonoscopy.
Study Overview
Study Type
Observational
Enrollment (Actual)
51
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Toledo, Ohio, United States, 43617
- ProMedica Toledo Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Male and female subjects 18 years or older scheduled for colonoscopy or EGD
Description
Inclusion Criteria:
- American Society of Anesthesiologists (ASA) I and II
- male and female
- Scheduled for routine colonoscopy or EGD
- ≥18 years of age
- Able to read, speak, and understand English
Exclusion Criteria:
- Physical or psychological condition which would impair trial participation, at the discretion of the PI
- BMI ≥ 35
- Pregnancy or lactation
- Known or suspected hypersensitivity to propofol or fentanyl
- Use of a fentanyl patch
- Allergies to eggs, egg products soybeans or soy products
- Diagnosis of sleep apnea
- Gastroparesis
- Full stomach at the time of procedure
- Participation in any other investigational device or drug study within 30 days of enrollment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
SEDASYS System
|
propofol sedation with the SEDASYS System
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent of documented responses/actions taken in response to SEDASYS System alarms (oxygen desaturation, apnea, hypotension, and bradycardia alarms)
Time Frame: <24 hours, i.e., for duration of study procedure
|
<24 hours, i.e., for duration of study procedure
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Fraction of users responses/actions to oxygen desaturation, apnea, hypotension, and/or bradycardia alarms deemed sufficient by Endpoint Adjudication Committee (EAC)
Time Frame: assessment of sufficient alarms will be reviewed by EAC after 100, 400, and 866 subjects completed the study
|
assessment of sufficient alarms will be reviewed by EAC after 100, 400, and 866 subjects completed the study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: James F Martin, PhD, Ethicon Endo-Surgery, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2015
Primary Completion (Actual)
June 15, 2016
Study Completion (Actual)
June 15, 2016
Study Registration Dates
First Submitted
October 6, 2015
First Submitted That Met QC Criteria
October 9, 2015
First Posted (Estimate)
October 12, 2015
Study Record Updates
Last Update Posted (Actual)
March 24, 2017
Last Update Submitted That Met QC Criteria
March 22, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- SED-14-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.